International prognostic score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3383-3388

  Moccia, Alden A ^a   Donaldson, Jane ^a   Chhanabhai, Mukesh ^a   Hoskins, Paul J ^a   Klasa, Richard J ^a   Savage, Kerry J ^a   Shenkier, Tamara N ^a   Slack, Graham W ^a   Skinnider, Brian ^a   Gascoyne, Randy D ^a   Connors, Joseph M ^a   Sehn, Laurie H ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FREEDOM FREE PROGRESSION; HODGKIN DISEASE; HUMAN; INTERNATIONAL PROGNOSTIC SCORE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BRITISH COLUMBIA; DACARBAZINE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 84866755983     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.0910     Document Type: Article

References (27)

1. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
2. Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin's disease trial. N Engl J Med 346:1417-1418, 2002 (Pubitemid 34754624)
3. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607-614, 2003 (Pubitemid 46621893)
4. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
5. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 (Pubitemid 36682817)
6. Viviani S, Zinzani PL, Rambaldi A, et al: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365:203-212, 2011
7. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
8. Gobbi PG, Levis A, Chisesi T, et al: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate-and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198-9207, 2005
9. Gordon LI, Hong F, Fisher RI, et al: A randomized Phase III trial of ABVD vs Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An Intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Blood 116, 2010 (abstr 415)
10. Hoskin PJ, Lowry L, Horwich A, et al: Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 27:5390-5396, 2009
11. Johnson PW, Radford JA, Cullen MH, et al: Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol 23: 9208-9218, 2005
12. Braziel RM, Oyama K: Mistaken diagnoses of Hodgkin's disease. Hematol Oncol Clin North Am 11:863-892, 1997 (Pubitemid 27431150)
13. Glaser SL, Swartz WG: Time trends in Hodgkin's disease incidence: The role of diagnostic accuracy. Cancer 66:2196-2204, 1990
14. Hartge P, Devesa SS: Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res 52:5566s-5569s, 1992
15. Brosteanu O, Hasenclever D, Loeffler M, et al: Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Ann Hematol 83:176-182, 2004 (Pubitemid 38292239)
16. Landgren O, Algernon C, Axdorph U, et al: Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88:438-444, 2003 (Pubitemid 36547130)
17. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon: Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604-1608, 1985 (Pubitemid 15062653)
18. Hutchings M, Gallamini A: Functional imaging, in Engert A, Horning S (eds): Hodgkin Lymphoma: Berlin, Germany, Springer-Verlag, 2011, pp 81-82
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
21. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
22. van Rijswijk RE, Haanen C, Dekker AW, et al: Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 7:1776-1782, 1989
23. Steidl C, Connors JM, Gascoyne RD: Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment. J Clin Oncol 29:1812-1826, 2011
24. Chetaille B, Bertucci F, Finetti P, et al: Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113:2765-3775, 2009
25. Sánchez-Aguilera A, Montalbán C, de la Cueva P, et al: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108:662-668, 2006 (Pubitemid 44061368)
26. Steidl C, Lee T, Shah SP, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885, 2010
27. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007